The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study. - Wikidata - wikimedia - TriplyDB

The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.

The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.

http://www.wikidata.org/entity/Q27851744

about

Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA Analysis CIViC database Sunitinib: the antiangiogenic effects and beyond Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials.Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases.Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension.Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib.Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma.Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor.A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer.Optimization of Early Response Monitoring and Prediction of Cancer Antiangiogenesis Therapy via Noninvasive PET Molecular Imaging Strategies of Multifactorial Bioparameters What are the current outcomes of advanced gastrointestinal stromal tumors: who are the long-term survivors treated initially with imatinib?Hypothyroidism after a cancer diagnosis: etiology, diagnosis, complications, and management Clinical relevance of pharmacogenetics in gastrointestinal stromal tumor treatment in the era of personalized therapy.Impact of VEGF gene polymorphisms in elderly cancer patients: clinical outcome and toxicity.Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia.miRNA-221 and miRNA-222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumours.microRNA-218 increase the sensitivity of gastrointestinal stromal tumor to imatinib through PI3K/AKT pathway.Gastrointestinal stromal tumors (GIST): Facing cell death between autophagy and apoptosis.Vinblastine-induced apoptosis of melanoma cells is mediated by Ras homologous A protein (Rho A) via mitochondrial and non-mitochondrial-dependent mechanisms.An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure.Response to sunitinib of a gastrointestinal stromal tumor with a rare exon 12 PDGFRA mutation.Olmesartan decreases IL-1β and TNF-α levels; downregulates MMP-2, MMP-9, COX-2, and RANKL; and upregulates OPG in experimental periodontitis.Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors.Treatment of gastrointestinal stromal tumours in paediatric and young adult patients with sunitinib: a multicentre case series.Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy.Clinical significance of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 gene polymorphisms in patients with gastrointestinal stromal tumors.Genomic Subtypes of GISTs for Stratifying Patient Response to Sunitinib following Imatinib Resistance: A Pooled Analysis and Systematic Review

P2860

29bd1bc6106cae42e471be46a033883710741b57

P248

Q26800005-C7A8CF58-D80F-4581-92C6-4DDE411AD619 Q27612411-CC41F22C-DF74-496F-9F5A-DFED8380B8A0 Q28066499-7928FEB9-3384-4634-8417-61EFFBAB63AE Q28069560-94C1B487-2894-4C4C-9901-F1F04CFAD20D Q33633431-A0CEB852-8173-42B5-99CB-E3A97888F7B7 Q33814571-96DA3EC2-9556-4039-9F82-3AFA7E735513 Q34403301-AE2ADC98-AF8C-422A-A745-A1AF61D74D49 Q34468729-FE643B96-FD3C-46C6-852E-CC66BB56D0F9 Q34662946-E0F3BE80-8481-4377-B98D-9F10E2F73162 Q35895558-105F9378-E225-4920-9BCB-3A35013C21BD Q35921573-FA2A9F1A-BBB5-4840-BB4C-BEBB3D789DAE Q36125976-D1988A8D-370E-46E3-A513-AFF9E008A409 Q36697575-221BF209-BF4D-4DD2-BD7F-5B3D4DEE1A15 Q37291272-446B2EF8-D395-442D-BC1F-CE57294D4CDC Q37342226-68900A13-5062-4026-8440-5E4CDF25590B Q37519042-C333BF9E-9E3B-4B8B-B13A-4BA5DFE6C998 Q38112821-8AA68F6B-A763-4433-86A7-E4DA68E7C960 Q38307997-3031B706-E626-4E65-8FBE-80BBC01C665C Q38826494-403366B1-4486-4D47-BE70-C4C6D66D17B6 Q38883917-7B1B8F84-6485-40F6-AF8A-8D4B4187A26A Q39007220-9979DE53-01C9-402E-B60A-74DE27D8F113 Q39068344-803ECB93-A989-484D-ABF5-EAB818EF1303 Q39169845-B445BB96-20BC-424C-BD7C-E94C96C6C3BB Q40452107-532AEC24-7858-42C0-9595-58401374EF5B Q43243489-916FC5DE-560E-4B3B-B90F-6DAD9D5E6E7B Q44001600-A33B0442-9DE8-4C08-90BA-6DD7B205B607 Q46783356-40E0AA3D-3798-401C-960C-AF46570C37D7 Q47114063-358EC8A0-5468-474F-AAB7-A77EEAD0F78A Q53142244-DB98BC33-2D13-4B23-BE3F-B6AAEC04436E Q53335025-B6E9B58A-C245-4284-8009-B11311572860 Q58702198-6AC790E8-CDFC-4B1E-8671-A24F51BC5301

P2860

The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.

http://www.wikidata.org/entity/Q27851744

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

The outcome and predictive fac ...... ilure - one institution study.

@ast

The outcome and predictive fac ...... ilure - one institution study.

@en

The outcome and predictive fac ...... ilure - one institution study.

@nl

type

label

The outcome and predictive fac ...... ilure - one institution study.

@ast

The outcome and predictive fac ...... ilure - one institution study.

@en

The outcome and predictive fac ...... ilure - one institution study.

@nl

altLabel

The outcome and predictive fac ...... ailure - one institution study

@en

prefLabel

The outcome and predictive fac ...... ilure - one institution study.

@ast

The outcome and predictive fac ...... ilure - one institution study.

@en

The outcome and predictive fac ...... ilure - one institution study.

@nl

P1433

Q27851744-F4668FCE-2FC7-4852-A1A7-765402B8CA96

P1476

Q27851744-948BEF2C-D31C-4D3F-98B1-7A81FA5F3047

P2093

Q27851744-065DDF11-6D76-4244-AC3C-7FB1460AE01C

Q27851744-1CCA5B06-2A12-4E9F-8900-36AF53E5C631

Q27851744-308B00D9-B04D-4A36-AB6A-4D20C19C09A9

Q27851744-545498C8-D8EB-40B4-A316-95E2866A413A

Q27851744-57270C9E-D17B-4092-9C98-7FEA3EADDCFE

Q27851744-6DE80C23-4B71-4015-8430-BCB0F27F0C3C

Q27851744-79404115-709C-4FA0-8084-0BEB44C6D5BD

Q27851744-7F709441-B598-4155-85A2-75D1A673435D

Q27851744-8487D782-6A6E-43D9-A69D-CDA4BABD7991

Q27851744-8603BCCB-8936-4D78-B686-209A431891D5

P2860

Q27851744-004784DE-4070-4B16-82D9-EB0961682278

Q27851744-0942F104-3541-4DD4-8E25-892B9289DF43

Q27851744-0A151A09-1308-4349-8D2A-CD2FAC3C4182

Q27851744-20A55405-DAD1-4C9D-BFBF-B4911AF36AA4

Q27851744-2435B183-16B6-4B83-92B7-9A0B8FCBD45A

Q27851744-2C86A5BC-276F-4BAE-B000-B9BF759FD4A7

Q27851744-2EA76957-9208-4E5E-B836-E11D023FE7F4

Q27851744-3676BBE9-7FF8-4708-BDED-ADB03EE17321

Q27851744-3C1F6F1B-AECC-445F-9ADD-9EAF3D26110E

Q27851744-43424062-30E6-44D9-A70D-B191F06C5D33

P2888

Q27851744-0C47E7CC-241C-4A41-A9D1-9FFD160FDB81

P304

Q27851744-05A574B2-30D4-4B94-924B-37915B234D44

P31

Q27851744-D158B0D5-12D9-42C1-9E1B-CC1C483A3701

P3181

Q27851744-4382C9C1-3A73-4B29-B684-D3CC97BDF051

P356

Q27851744-73828108-BF22-41FD-8B80-A8B87C64E665

P407

Q27851744-E802767A-5F2E-4DCB-9DC0-F8E440F83403

P433

Q27851744-07C49584-9917-4F4B-B4EC-E3E38A0BA0EE

P478

Q27851744-366601FA-5B9C-4CA4-80FE-EB9366C960CC

P50

Q27851744-93BA0F22-691A-4D22-9917-898B508BB76C

Q27851744-9D14F659-FDFE-40B8-A132-DF6C3BA475F9

P577

Q27851744-359EE4D8-D487-4192-AECB-D939B09B52E7

P5875

Q27851744-DE44242D-254A-4C1F-AC9A-B6A84589D372

P6179

Q27851744-E512F92B-481B-4C19-9A8B-4BBAA0775C27

P698

Q27851744-774CCE00-CEBA-4882-AD4A-3859DDE9D403

P932

Q27851744-25FA0CF1-462A-4304-8E98-6069A0EC36C5

P3181

P356

1471-2407-12-107

P1433

P1476

The outcome and predictive fac ...... ilure - one institution study.

@en

P2093

Agnieszka Woźniak

http://www.w3.org/2001/XMLSchema#string

Anna Klimczak

http://www.w3.org/2001/XMLSchema#string

Czesław Osuch

http://www.w3.org/2001/XMLSchema#string

Elżbieta Bylina

http://www.w3.org/2001/XMLSchema#string

Ewa Mierzejewska

http://www.w3.org/2001/XMLSchema#string

Iwona Lugowska

http://www.w3.org/2001/XMLSchema#string

Jacek Kroc

http://www.w3.org/2001/XMLSchema#string

Janusz A Siedlecki

http://www.w3.org/2001/XMLSchema#string

Kacper Wasielewski

http://www.w3.org/2001/XMLSchema#string

Magdalena Brzeskwiniewicz

http://www.w3.org/2001/XMLSchema#string

P2860

KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients

Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.

Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib.

Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.

P2888

1471-2407-12-107

P304

107

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3581633

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/1471-2407-12-107

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Piotr Rutkowski

P577

2012-03-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221968493

http://www.w3.org/2001/XMLSchema#string

P6179

1002590166

http://www.w3.org/2001/XMLSchema#string

P698

22439647

http://www.w3.org/2001/XMLSchema#string

P932

3361487

http://www.w3.org/2001/XMLSchema#string